Medical Fund

MEDRX No Load Class


  • Invests in patented first line pharmaceuticals and biologics as these products tend to have high profit margins and significant barriers to entry.
  • Employs a long-term perspective seeking to capture returns of both intrinsic valuation realization and scientific discovery.
  • The Bio-Pharma sector is relatively insensitive to economic turmoil, while novel research and development imply sustained growth.

Medical Fund Commentary

Read more about the Medical Fund in this commentary.

Medical Fund Fact Sheet

Learn more about the Medical Fund in this fact sheet.

Performance Overview


The Medical Fund No Load Class inception date is 9/30/1999.  Figures include changes in principal value, reinvested dividends and capital gains distributions.  Performance data quoted represents past performance and does not guarantee future results.  Investment return and principal value will vary, and shares may be worth more or less at redemption than at original purchase.  The most recent month-end performance data is listed below, or you may obtain it by calling us at 1-800-930-3828.  Current performance may be lower or higher than the performance data quoted.  Performance data does not reflect the deduction of the sales load or fee which, if reflected, would reduce the performance quoted.  You will be charged a redemption fee equal to 2.00% of the net amount of the redemption if you redeem or exchange your shares 30 days or less after you purchase them.

Portfolio Characteristics

As of June 30, 2022

Portfolio Managers

Paul Abel

Senior Portfolio Manager

Paul joined the firm in 1999 and currently serves as Portfolio Manager to the Kinetics Medical Fund and various other private funds. Paul’s primary ...


Daily Performance

As of September 26, 2022
Benchmark Daily NAV One Day Return (%) Month to Date Quarter to Date Year to Date
MEDRX $27.85 -1.24% -2.69% -8.63% -9.52%
S&P 500 Index TR $16,764.28 -1.03% -7.48% -3.07% -22.42%
Nasdaq Index $10,802.92 -0.60% -8.58% -2.05% -30.95%

Total Return (Annualized)

As of June 30, 2022
Benchmark 1YR 3YR 5YR 10YR Since Inception
MEDRX -5.39% 9.92% 7.40% 10.29% 8.92%
S&P 500 Index TR -10.62% 10.60% 11.31% 12.96% 6.88%
Nasdaq Index -23.96% 11.27% 12.43% 14.15% 6.30%

Historical Total Return

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
MEDRX 57.04% -13.77% -29.14% 23.19% 6.96% -0.72% 14.81% 15.47% -20.42% 24.47% 4.30% 5.11% 8.86% 49.25% 16.44% 6.59% -8.01% 10.71% 1.67% 16.04% 9.04% 10.59%
S&P 500 Index TR -9.10% -11.89% -22.10% 28.68% 10.88% 4.91% 15.79% 5.49% -37.00% 26.46% 15.06% 2.11% 16.00% 32.39% 13.69% 1.38% 11.96% 21.83% -4.38% 31.49% 18.40% 28.71%
Nasdaq Index -39.29% -21.05% -31.53% 50.01% 8.59% 1.37% 9.52% 9.81% -40.54% 43.89% 16.91% -1.80% 15.91% 38.32% 13.40% 5.73% 7.50% 28.24% -3.88% 35.23% 43.64% 21.39%

Class Information

Class Ticker CUSIP 12b-1 Fee Net Expense Ratio Gross Expense Ratio
No Load Class MEDRX 494613102 - 1.39% 2.18%
Advisor A KRXAX 494613847 0.50% 1.64% 2.43%
Advisor C KRXCX 494613755 1.00% 2.14% 2.92%

Fund Statistics

As of June 30, 2022
MEDRX S&P 500 Index TR
Beta 0.68 1.00
Standard Deviation 16.86 15.22
Up Market Capture Ratio 0.85 -
Down Market Capture Ratio 0.65 -
Sharpe Ratio 0.44 0.35
Weighted Avg. Mkt. Cap ($mil) $188,916 $483,503
Median Market Capitalization $17,608 $27,160
Price to Book 4.75 3.52
Price to Earnings 17.48 18.50
Return on Equity 34.34% 27.38%
Active Share 93.75% -

Top 10 Holdings (%)

As of June 30, 2022
Holdings Percent
Bristol-Myers Squibb Company 10.0%
Eli Lilly & Co. 9.8%
Pfizer, Inc. 8.7%
AbbVie, Inc. 8.4%
Merck & Co., Inc. 7.0%
Johnson & Johnson 6.8%
Novartis AG - ADR 6.5%
AMGEN, Inc. 5.4%
AstraZeneca plc - ADR 5.1%
Biogen, Inc. 4.2%

Top 10 Industries (%)

As of June 30, 2022
Title Percent
Pharmaceutical and Medicine Manufacturing 87.9%
Chemical Manufacturing 7.7%
Professional, Scientific, and Technical Services 2.0%
Machinery Manufacturing 1.1%
Ambulatory Health Care Services 0.2%
Biotechnology 0.0%
Scientific Research and Development Services 0.0%


The Medical Fund is classified as a non-diversified fund. Therefore, the value of its shares may fluctuate more than shares invested in a broader range of industries. You should consult the Fund’s prospectus for a complete list of risks associated with your investment.

You should consider the investment objectives, risks, charges and expenses of the fund carefully before investing.  For a free copy of the fund’s prospectus, which contains this and other information, you may click here or call us at 1-800-930-3828.  You should read the prospectus carefully before you invest.

S&P 500 Index statistics data is based on the iShares S&P 500 Index Fund for market cap, price to book, price to earnings, return on equity, and active share. iShares is a product of BlackRock, Inc.

The NASDAQ Composite (NASDAQ) and the Standard & Poor’s 500 Index (S&P 500) each represent an unmanaged, broad-based basket of stocks. They are typically used as a proxy for overall market performance. NASDAQ Composite returns stated above do NOT include reinvested dividends, while the S&P 500 Index returns assume that dividends are reinvested. An investor cannot invest directly in an index.

The Growth of $10,000 chart illustrates the performance of a hypothetical $10,000 investment made in No Load Class shares commencement of operations (9/30/99). It assumes reinvestment of capital gains and dividends. This chart is not intended to imply any future performance.

Holdings are expressed as a percentage of total net investments and may vary over time. Equity holdings are subject to change, and may not be indicative of actual market position due to the use of call and put options.

The Top Industries displayed represent a percentage of the net assets and excludes cash equivalents and other assets in excess of liabilities.

Assets represent the total net assets for the specified portfolio, which includes all fund classes.

The Gross expense ratios listed are as of 12/31/2020 as reported in the 4/30/2021 prospectus. The Fund’s adviser voluntarily agreed to waive management fees and reimburse fund expenses so that net annual fund operating expenses do not exceed certain levels, not including acquired fund fees and expenses (AFFE), through May 1, 2022 and may be discontinued at any time by the Fund’s adviser after May 1, 2022.

*Number of Positions are calculated such that all securities issued by one issuer are counted as one position.


Beta: A statistic that measures the volatility of the fund, as compared to the overall market. The market’s beta is set at 1.00; therefore a beta higher than 1.00 is considered to be more volatile than the market, while a beta lower than 1.00 is considered to be less volatile. It is important to note that a low beta for a fund does not necessarily imply that the fund has a low level of volatility, a low beta signifies only that the fund’s market-related risk is low.  The Beta has been calculated since inception.

Standard Deviation: A statistical measure of portfolio risk used to measure variability of total return around an average, over a specified period of time. The greater the standard deviation over the period, the wider the variability or range of returns and hence, the greater the fund’s volatility. The standard deviation has been calculated since inception.

Up Market Capture Ratio: A statistical measure of an investment manager’s overall performance in up-markets. The up-market capture ratio is used to evaluate how well an investment manager performed relative to an index during periods when that index has risen. The up-market capture ratio has been calculated since inception.

Down Market Capture Ratio: A statistical measure of an investment manager’s overall performance in down-markets. The down-market capture ratio is used to evaluate how well or poorly an investment manager performed relative to an index during periods when that index has dropped. The down-market capture ratio has been calculated since inception.

Sharpe Ratio: A statistical measure that uses standard deviation and excess return to determine reward per unit of risk. A higher Sharpe ratio implies a better historical risk-adjusted performance. The Sharpe ratio has been calculated since inception using the 3-month treasury bill for the risk-free rate of return.

Weighted Avg. Mkt. Cap: The mean market capitalization (value of outstanding shares) of a basket of stocks, taking into account the relative weight of each investment.

Median Market Capitalization: The median market capitalization (value of outstanding shares) of a basket of stocks.

Price to Book Ratio: The harmonic weighted average of the price/book (P/B) ratios of the equity securities referenced. The ratio calculated by dividing the current price of the stock by the company’s book value per share (assets minus liabilities).

Price to Earnings Ratio: The harmonic weighted average of the price/earnings (P/E) ratios of the equity securities referenced. The P/E ratio is calculated by dividing the current price of the stock by the trailing one year earnings.

Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation’s profitability by revealing how much profit a company generates with the money shareholders have invested.

Turnover Ratio: A measure of how frequently assets within a fund are bought and sold by the managers represented over a one year period.

Active share: A measure of the percentage of holdings in a portfolio that differ from a benchmark index. It is calculated by taking the sum of the differences of the weight of each holding in the portfolio and the weight of each holding in the benchmark index and dividing by two. Active Share Ratio: Active share is measured against the iShares S&P 500 ETF.